{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:00:18Z","timestamp":1790730018607,"version":"4.1.0"},"reference-count":27,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Activating RET alterations have been reported in a variety of solid tumors, including pheochromocytoma where they occur both sporadically and as part of familial multiple endocrine neoplasia type 2 (MEN2) syndromes. Selpercatinib is a first-in-class, highly selective, and potent small molecule RET kinase inhibitor that has demonstrated marked and durable antitumor activity in diverse RET-activated solid tumors in the LIBRETTO-001 study (NCT03157128).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We describe the first 6 pheochromocytoma cases treated with selpercatinib in the LIBRETTO-001 study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 6 patients (1 sporadic and 5 reported as part of MEN2 syndromes) in this case report, 4 had a partial response\/complete response and 2 had stable disease per independent review committee. Treatment duration ranged from 9.2 months to more than 56.4 months. The safety profile of treatment was consistent with selpercatinib in other indications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>These data support selpercatinib as an effective therapy against RET-mutant pheochromocytoma, adding to the diversity of RET-activated tumor types that may benefit from targeted RET inhibition.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgae283","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T11:21:52Z","timestamp":1714044112000},"page":"e600-e606","source":"Crossref","is-referenced-by-count":21,"title":["Clinical Activity of Selpercatinib in <i>RET<\/i>-mutant Pheochromocytoma"],"prefix":"10.1210","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5831-5150","authenticated-orcid":false,"given":"Barbara","family":"Deschler-Baier","sequence":"first","affiliation":[{"name":"Comprehensive Cancer Center, University Hospital W\u00fcrzburg , 97080 W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavana","family":"Konda","sequence":"additional","affiliation":[{"name":"The Ohio State University, Comprehensive Cancer Center , Columbus, OH 43210 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erminia","family":"Massarelli","sequence":"additional","affiliation":[{"name":"City of Hope Medical Center , Duarte, CA 91010 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0355-030X","authenticated-orcid":false,"given":"Mimi I","family":"Hu","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center , Houston, TX 77030 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori J","family":"Wirth","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital , Boston, MA 02114 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojian","family":"Xu","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN 46285 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Wright","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN 46285 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick J","family":"Clifton-Bligh","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Royal North Shore Hospital , St Leonards, NSW 2065 ,","place":["Australia"]},{"name":"Kolling Institute of Medical Research, University of Sydney , Sydney, NSW 2065 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"issue":"3","key":"2025021815500773400_dgae283-B1","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1006\/bbrc.1993.2392","article-title":"Exon structure and flanking intronic sequences of the human RET proto-oncogene","volume":"196","author":"Ceccherini","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"issue":"18","key":"2025021815500773400_dgae283-B2","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1101\/gad.205001","article-title":"Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis","volume":"15","author":"de Graaff","year":"2001","journal-title":"Genes Dev"},{"issue":"10","key":"2025021815500773400_dgae283-B3","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0168-9525(01)02420-9","article-title":"The RET receptor: function in development and dysfunction in congenital malformation","volume":"17","author":"Manie","year":"2001","journal-title":"Trends Genet"},{"issue":"49","key":"2025021815500773400_dgae283-B4","doi-asserted-by":"crossref","first-page":"5590","DOI":"10.1038\/sj.onc.1203857","article-title":"The RET proto-oncogene in human cancers","volume":"19","author":"Jhiang","year":"2000","journal-title":"Oncogene"},{"issue":"7","key":"2025021815500773400_dgae283-B5","doi-asserted-by":"crossref","first-page":"855","DOI":"10.6004\/jnccn.2019.0033","article-title":"Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Ajani","year":"2019","journal-title":"J Natl Compr Cancer Netw"},{"issue":"3","key":"2025021815500773400_dgae283-B6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrc3680","article-title":"RET revisited: expanding the oncogenic portfolio","volume":"14","author":"Mulligan","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2025021815500773400_dgae283-B7","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/MPA.0b013e3181ebb4f0","article-title":"The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer","volume":"39","author":"Chen","year":"2010","journal-title":"Pancreas"},{"issue":"2","key":"2025021815500773400_dgae283-B8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer cell"},{"issue":"2","key":"2025021815500773400_dgae283-B9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/hmg\/3.2.237","article-title":"Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours","volume":"3","author":"Eng","year":"1994","journal-title":"Hum Mol Genet"},{"issue":"3","key":"2025021815500773400_dgae283-B10","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s12020-020-02332-2","article-title":"MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives","volume":"69","author":"Amodru","year":"2020","journal-title":"Endocrine"},{"issue":"3","key":"2025021815500773400_dgae283-B11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-8587(18)30336-X","article-title":"Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study","volume":"7","author":"Castinetti","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"2025021815500773400_dgae283-B12","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1210\/jc.2013-1907","article-title":"One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma","volume":"98","author":"Hescot","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025021815500773400_dgae283-B13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/cen.12590","article-title":"Treatment of malignant phaeochromocytoma with a combination of cyclophosphamide, vincristine and dacarbazine: own experience and overview of the contemporary literature","volume":"82","author":"Deutschbein","year":"2015","journal-title":"Clin Endocrinol (Oxf"},{"key":"2025021815500773400_dgae283-B14"},{"key":"2025021815500773400_dgae283-B15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40200-016-0226-x","article-title":"Does this patient have pheochromocytoma? A systematic review of clinical signs and symptoms","volume":"15","author":"Soltani","year":"2015","journal-title":"J Diabetes Metab Disord"},{"issue":"6","key":"2025021815500773400_dgae283-B16","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.jpainsymman.2008.12.002","article-title":"An unusual case of severe constipation due to metastatic pheochromocytoma","volume":"37","author":"Mason","year":"2009","journal-title":"J Pain Symptom Manage"},{"issue":"9","key":"2025021815500773400_dgae283-B17","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"2025021815500773400_dgae283-B18","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"2025021815500773400_dgae283-B19","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"key":"2025021815500773400_dgae283-B20","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/PO.21.00127","article-title":"Novel RET fusion RET-SEPTIN9 predicts response to selective RET inhibition with selpercatinib in malignant pheochromocytoma","volume":"5","author":"Mweempwa","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"11","key":"2025021815500773400_dgae283-B21","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1210\/clinem\/dgac471","article-title":"Targeted therapies in pheochromocytoma and paraganglioma","volume":"107","author":"Wang","year":"2022","journal-title":"J Clin Endocrinol Metabol"},{"issue":"2","key":"2025021815500773400_dgae283-B22","doi-asserted-by":"crossref","first-page":"101354","DOI":"10.1016\/j.beem.2019.101354","article-title":"Metastatic pheochromocytoma and paraganglioma: management of endocrine manifestations, surgery and ablative procedures, and systemic therapies","volume":"34","author":"Jasim","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"issue":"2","key":"2025021815500773400_dgae283-B23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized management of pheochromocytoma and paraganglioma","volume":"43","author":"N\u00f6lting","year":"2022","journal-title":"Endocr Rev"},{"issue":"5","key":"2025021815500773400_dgae283-B24","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2265.1993.tb00350.x","article-title":"Phaeochromocytoma in multiple endocrine neoplasia type 2 A: survey of 100 cases","volume":"38","author":"Casanova","year":"1993","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2025021815500773400_dgae283-B25","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2796.1995.tb01211.x","article-title":"Pheochromocytoma in multiple endocrine neoplasia type 2: european study. The Euromen Study Group","volume":"238","author":"Modigliani","year":"1995","journal-title":"J Intern Med"},{"issue":"6","key":"2025021815500773400_dgae283-B26","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S1470-2045(14)70154-8","article-title":"Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study","volume":"15","author":"Castinetti","year":"2014","journal-title":"Lancet Oncol"},{"key":"2025021815500773400_dgae283-B27","doi-asserted-by":"crossref","first-page":"S621","DOI":"10.1016\/j.annonc.2021.08.702","article-title":"First international randomized study in malignant progressive pheochromocytoma and paragangliomas (FIRSTMAPPP): an academic double-blind trial investigating sunitinib","volume":"32","author":"Baudin","year":"2021","journal-title":"Ann Oncol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae283\/57451245\/dgae283.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/3\/e600\/57451245\/dgae283.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/3\/e600\/57451245\/dgae283.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:09:33Z","timestamp":1739894973000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/3\/e600\/7657869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,4,25]]},"published-print":{"date-parts":[[2025,2,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae283","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,4,25]]}}}